Actively Recruiting

Phase 3
Age: 6Months - 75Years
All Genders
NCT05462587

A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II

Led by AUG Therapeutics · Updated on 2026-05-01

4

Participants Needed

1

Research Sites

226 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).

CONDITIONS

Official Title

A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II

Who Can Participate

Age: 6Months - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants must be between 6 months and 75 years old
  • Confirmed biochemical and genetic diagnosis of Leukocyte Adhesion Deficiency Type II (SLC35C1-CDG)
  • Documented history of Lewis antigen deficiency
  • History of recurrent infections, opportunistic infections, or infections not responding well to standard care
  • Written informed consent provided by participant or guardian; assent provided by minors as appropriate
  • Ability and willingness to follow study protocol
  • Women of childbearing potential must be non-lactating, have a negative pregnancy test at screening, and use acceptable double-barrier contraception during the study and 30 days after last dose
  • Male participants must agree to use acceptable double-barrier contraception during the study and 30 days after last dose
Not Eligible

You will not qualify if you...

  • Severe anemia with hemoglobin below 8.0 g/dL (4.9 mmol/L)
  • Impaired kidney function with estimated glomerular filtration rate below 90 mL/min
  • Total absence of fucosylation on red blood cells combined with presence of anti-H antigen
  • Known or suspected allergy or intolerance to fucose or any ingredients of the study drug
  • History of not responding to adequate dosing of fucose as judged by the investigator
  • Inability or unwillingness to comply with study requirements as judged by the investigator
  • Pregnancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Mayo Clinic

Rochester, Minnesota, United States, 55905

Actively Recruiting

Loading map...

Research Team

J

Jennifer Lin

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here